Recombinant factor VIIa (NovoSeven®) and the safety of treatment

This publication has 11 references indexed in Scilit:

• rFVIIa – Its Thrombogenicity
  Thrombosis and Haemostasis, 2000
• A randomized, double‐blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors
  Haemophilia, 1998
• Safety, efficacy and lessons from continuous infusion with rFVIIa
  Haemophilia, 1998
• Prospective, Randomised Trial of Two Doses of rFVIIa (NovoSeven) in Haemophilia Patients with Inhibitors Undergoing Surgery
  Thrombosis and Haemostasis, 1998
• Home Treatment of Mild to Moderate Bleeding Episodes Using Recombinant Factor VIIa (Novoseven) in Haemophiliacs with Inhibitors
  Thrombosis and Haemostasis, 1998
• Recombinant Activated Factor VII in the Treatment of Bleeding Episodes in Patients With Inherited and Acquired Bleeding Disorders
  Transfusion Medicine Reviews, 1993
• Disseminated intravascular coagulation and hemorrhage in hemophilia B following elective surgery
  American Journal of Hematology, 1990
• Factor VIIa in the treatment of haemophilia
  Blood Coagulation & Fibrinolysis, 1990
• SUCCESSFUL USE OF RECOMBINANT FACTOR VIIa IN PATIENT WITH SEVERE HAEMOPHILIA A DURING SYNOVECTOMY
  The Lancet, 1988
• MYOCARDIAL INFARCTION COMPLICATING ACTIVATED PROTHROMBIN COMPLEX CONCENTRATE SUBSTITUTION IN PATIENT WITH HAEMOPHILIA A
  The Lancet, 1982